MK-2060
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease
Conditions
End-Stage Renal Disease, Kidney Failure, Chronic
Trial Timeline
May 30, 2022 → Feb 14, 2023
NCT ID
NCT05335005About MK-2060
MK-2060 is a phase 1 stage product being developed by Merck for End-Stage Renal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05335005. Target conditions include End-Stage Renal Disease, Kidney Failure, Chronic.
What happened to similar drugs?
8 of 9 similar drugs in End-Stage Renal Disease were approved
Approved (8) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05335005 | Phase 1 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease